Yuhan Corp, based in South Korea, is a pharmaceutical company with an ESG score of 32.7, signifying high risk. Specializing in primary and specialty care, dietary supplements, household and animal care, as well as contract manufacturing of active pharmaceutical ingredients, Yuhan provides a range of services from research and development to commercial production. Its offerings include treatments for antivirals, antibiotics, antihistamines, antidiabetics, and more, catering to international markets.